Literature DB >> 12873814

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.

Justiniano Santos1, Ramon Planas, Albert Pardo, Rosa Durández, Eduard Cabré, Rosa Maria Morillas, Maria Luisa Granada, José Angel Jiménez, Enrique Quintero, Miquel Angel Gassull.   

Abstract

BACKGROUND/AIMS: The most rational treatment of moderate ascites is spironolactone alone or in combination with furosemide. However, it is unknown which of these two treatment schedules is preferable.
METHODS: One hundred nonazotemic cirrhotic patients with moderate ascites were randomly assigned to be treated with spironolactone and furosemide (Group 1: 50 patients) or with spironolactone alone (Group 2: 50 patients). If no response was obtained, the doses of diuretics were increased up to 400 mg/day of spironolactone and 160 mg/day of furosemide. In patients of group 2 not responding to 400 mg/day of spironolactone, furosemide was added. In cases with an excessive response, the dosage of diuretics was reduced.
RESULTS: The response rate (98% in Group 1 vs. 94% in Group 2), the rapidity of ascites mobilization and the incidence of complications induced by diuretic therapy was similar in both groups. The need to reduce the diuretic dosage was significantly higher in Group 1 than Group 2 (68% vs. 34%; P=0.002).
CONCLUSIONS: In the treatment of moderate ascites, spironolactone alone seems to be as safe and effective as spironolactone associated with furosemide. Since spironolactone alone requires less dose adjustment, it would be more suitable for treating ascites on an outpatient basis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873814     DOI: 10.1016/s0168-8278(03)00188-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

2.  Liver: diuretic agents for ascites: joining forces from the start?

Authors:  Pere Ginès
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 46.802

3.  Management of Cardio-Renal Syndrome and Diuretic Resistance.

Authors:  Frederik H Verbrugge; Wilfried Mullens; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

Review 4.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

5.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

6.  Response criteria of tolvaptan for the treatment of hepatic edema.

Authors:  Yasunari Hiramine; Haruki Uojima; Hiroyuki Nakanishi; Akira Hiramatsu; Takuya Iwamoto; Mutsuumi Kimura; Hideto Kawaratani; Shuji Terai; Hitoshi Yoshiji; Hirofumi Uto; Isao Sakaida; Namiki Izumi; Kiwamu Okita; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2017-06-29       Impact factor: 7.527

Review 7.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 8.  Management of ascites and hepatorenal syndrome.

Authors:  Salvatore Piano; Marta Tonon; Paolo Angeli
Journal:  Hepatol Int       Date:  2017-08-23       Impact factor: 6.047

9.  Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.

Authors:  João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Mário Santos; Henrique Cyrne Carvalho; Paulo Bettencourt; David Kénizou; Javed Butler; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2015-11-28       Impact factor: 5.460

10.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.